Senzime AB (SNZZF)
0.4786
0.00 (0.00%)
USD |
OTCM |
Jun 09, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 75.24M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -7.13% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 6.661 |
| Price to Book Value | 2.528 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0769 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 91.63% |
Profile
| Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. It manufactures products for automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patient's neuromuscular function perioperatively and in the intensive care medicine setting. The company also distributes bioreactor systems for the pharmaceutical industry. Senzime was founded by Thomas Ambjorn Carlsson in 1999 and is headquartered in Uppsala, Sweden. |
| URL | http://www.senzime.com |
| Investor Relations URL | N/A |
| HQ State/Province | Uppsala |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. It manufactures products for automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patient's neuromuscular function perioperatively and in the intensive care medicine setting. The company also distributes bioreactor systems for the pharmaceutical industry. Senzime was founded by Thomas Ambjorn Carlsson in 1999 and is headquartered in Uppsala, Sweden. |
| URL | http://www.senzime.com |
| Investor Relations URL | N/A |
| HQ State/Province | Uppsala |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |